A congressional investigation found that the US Food and Drug Administration’s “atypical collaboration” to approve a high-priced Alzheimer’s drug from Biogen was “rife with irregularities.”
Read More
An experimental Alzheimer’s drug from Biogen and partner Eisai modestly slowed the brain disease’s inevitable worsening, researchers report – but it remains unclear how much difference that might make in people’s lives.
Read More
Durham-based Praetego, a pharmaceutical company focused on treating neurodegenerative diseases related to aging, has received a $2.5 million grant from the National Institutes of Health to advance its lead drug candidate against Alzheimer’s disease.
Read More
An RTP based drug development firm backed by a Bill Gates-linked foundation has raised more than $6 million as it continues to develop an Alzheimer’s treatment.
Read More
Biogen expects “minimal” revenue this year from its Alzheimer’s treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that drew immediate criticism from doctors and patient advocates.
Read More
A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, extending a slow debut complicated by coverage questions and doctor concerns. The news came Wednesday as Biogen also confirmed making layoffs among its patient support staff in Raleigh.
Read More
At its core, the controversy about Biogen’s Aduhelm raises a fundamental question: Did the FDA approve a drug that doesn’t help people – and if so, why?
Read More
GlaxoSmithKline is committing up to $2.2 billion for potential drugs to treat Parkinson’s and Alzheimer’s as well as other diseases in a deal announced Friday with drug firm Alector.
Read More
Workers at Biogen’s huge Research Triangle Park biopharmaceutical manufacturing site at 5000 Davis Drive are producing the initial supplies of the Alzheimer’s treatment newly approved by the U.S. Food and Drug Administration.
Read More
